Monoclonal gammopathy of undetermined significance: a consensus statement.
On February 25, 2009, a panel of international experts on plasma cell dyscrasia and skeletal disease met to discuss monoclonal gammopathy of undetermined significance (MGUS). This non-malignant B-cell disorder is the most common plasma cell dyscrasia and is associated with an increased risk of developing serious B-cell disorders. Individuals with MGUS also have an increased risk of osteoporosis and osteopenia associated with an increased likelihood of developing fractures especially in the vertebral column, peripheral neuropathy and thromboembolic events. The goal of the meeting was to develop a consensus statement regarding the appropriate tests to screen, evaluate and follow-up patients with MGUS. The panel also addressed the identification and treatment of MGUS-related skeletal problems, thromboembolic events and neurological complications. The following consensus statement outlines the conclusions and marks the first time that a consensus statement for the screening and treatment of MGUS has been clearly stated.
Berenson
James R
JR
Institute for Myeloma & Bone Cancer Research, West Hollywood, CA 90069, USA. jberenson@imbcr.org
Anderson
Kenneth C
KC
Audell
Robert A
RA
Boccia
Ralph V
RV
Coleman
Morton
M
Dimopoulos
Meletios A
MA
Drake
Matthew T
MT
Fonseca
Rafael
R
Harousseau
Jean-Luc
JL
Joshua
Douglas
D
Lonial
Sagar
S
Niesvizky
Ruben
R
Palumbo
Antonio
A
Roodman
G David
GD
San-Miguel
Jesus F
JF
Singhal
Seema
S
Weber
Donna M
DM
Zangari
Maurizio
M
Wirtschafter
Eric
E
Yellin
Ori
O
Kyle
Robert A
RA
D000368:Aged; D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000209:etiology; D002471:Cell Transformation, Neoplastic; D018450:Disease Progression; D006801:Humans; D008134:Long-Term Care / Q000379:methods / Q000592:standards; D008403:Mass Screening / Q000379:methods / Q000458:organization & administration; D008875:Middle Aged; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy / Q000209:etiology; D011379:Prognosis; D012307:Risk Factors